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Abstract 
VALIDATION OF A WHOLE BLOOD SEROLOGY TEST FOR DIAGNOSING HELICOBACTER 
PYLORI IN CHINESE PATIENTS. 
Matthew S. Falk and Joseph J. Y. Sung. Department of Medicine and Therapeutics, Prince of Wales 
Hospital, Chinese University of Hong Kong, Shatin, Hong Kong. (Sponsored by Matthew E. Cohen, 
Department of Internal Medicine, Yale University School of Medicine). 
Purpose To assess the accuracy of the FlexPack HP (Abbott Laboratory), a rapid whole blood mimuno- 
chromatographic serology test, for diagnosing Helicobacter pylori infection in Hong Kong Chinese 
patients. 
Methods Consecutive patients with dyspepsia presenting for endoscopic examination were recruited for 
FlexPack HP testing. Those having received previous anti-// pylori therapy or those currently taking 
antibiotics or acid-suppressive drugs were excluded. In addition to having the FlexPack HP test, all patients 
were tested for H. pylori using histology, rapid urease test and a [13C] urea breath test. Patients were 
considered to be infected with H. pylori when two or more of these three reference tests were positive. 
Results One hundred patients were studied. The average age was 51 +/- 15 years (range 21-90 years), 
55% of whom were female. Endoscopy revealed gastric ulcers in 5%, duodenal ulcers in 6%, gastric 
erosions in 7%, gastric erythema in 20% and no apparent disease in 62%. Fifty-four (54%) of the patients 
had H. pylori infection based on study definitions. FlexPack HP test characteristics were: sensitivity 82% 
(95% CI: 73 - 88%), specificity 85% (95% CL 74 - 92%), positive predictive value 86% (95% CI: 77 - 
93%) and negative predictive value 80% (95% CI: 70 - 86%). A faint line, interpreted as positive, was seen 
in 15 (15%) of the FlexPack HP results. No invalid tests occurred as assessed by the control panel integral 
to the FlexPack HP test. 
Conclusion FlexPack HP was quick, convenient and accurate when used in a secondary care setting in 
Hong Kong Chinese patients. This test may be useful for in-office H. pylori testing. 
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Introduction 
History 
Our understanding of Helicobacter pylori and its role in peptic ulcer disease has 
increased dramatically since its re-discovery in 1982 by Marshall and Warren who 
isolated the bacterium from gastric biopsy specimens taken from patients with gastritis 
(1). At that time, the micro-aerophilic, curved, spiral-shaped bacillus was named 
Campylobacter pyloridis since it resembled other Campylobacters both morphologically 
and in guanine/cytosine DNA content; later the name became Campylobacter pylori and 
finally Helicobacter pylori (2, 3). This urease-producing organism exists in close 
association with the epithelium of the gastric lumen. By 1984, Marshall and Warren had 
presented and published this finding along with their discovery of the association of H. 
pylori infection with both gastritis and peptic ulcer disease (4). Marshall even went so far 
as to ingest the live organism purposely to demonstrate the acute effects of infection in an 
effort to fulfill Koch's postulates (5). 
Pathogenicity 
The role of H. pylori as an important human pathogen became increasingly 
defined over the following years. H. pylori is associated with chronic gastritis (6), and 
gastric and duodenal ulcers (7, 8). More questionable studies have associated H. pylori 
with gastric adenocarcinoma (9, 10) and gastric lymphoma (11, 12). H. pylori might 
contribute to non-ulcer dyspepsia (13), migraine headaches (14), hyperemesis gravidarum 
(15, 16), ischemic heart disease (17) or even childhood growth retardation (18), although 
dubious and conflicting studies exist in some cases (19). In 1994 H. pylori was given 
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grade I (i.e., definite) carcinogen status by the International Agency for Research on 
Cancer (20). 
Virulence 
Virulence factors have been identified for H. pylori which may determine the 
likelihood of developing disease and influence its severity. The two main virulence 
factors identified to date are the toxins produced by the genes vacA (vacuolating 
cytotoxin gene A) and cagA (cytotoxin associated gene A). Both vacA+ and ccigA + 
strains are isolated more often from patients with peptic ulcers than from those without 
ulcerative disease. The cagA+ strain is more often found in patients with gastric 
adenocarcinoma than in those without the disease (21). The increased inflammation 
caused by more virulent strains appears to be related to some of the gene products from 
the cag pathogenicity island, a region with cagA as the marker sequence. Furthermore, 
cytotoxicity of a strain is also affected by the vcicA genotype present, in that peptic 
ulceration is associated with the strain’s vcicA signal sequence (21). 
Although testing for the presence of the cagA marker sequence is the primary 
viable diagnostic option predictive of disease at this time, the natural history of infection 
caused by strains testing negative for cagA is not altogether clear. Determination of 
virulence factors remains a research goal, at present, and has not yet been incorporated 
into algorithms for the management of H. pylori (21). 
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Transmission 
H. pylori is a human pathogen with humans as the primary reservoir. However, a 
mode of transmission has yet to be determined with certainty. Most evidence points to 
both oral-oral and fecal-oral spread. Oral-oral spread is more likely the predominant 
means of transmission in developed countries, whereas the fecal-oral route probably 
accounts for most spread in developing countries (22). In addition, case reports exist of 
iatrogenic transmission via flexible endoscopes that have contacted multiple patients 
without proper disinfection (23). The housefly has been evaluated as a possible but 
unproven vector for transmission (24). Transmission of H. pylori in Asian populations 
was speculated to occur secondary to chopstick use, but this theory was rejected after 
further investigation (25). 
Epidemiology 
H. pylori infection is the world’s most common human chronic bacterial 
infection, with a world-wide prevalence of at least 50 to 60% (26, 27). However, 
prevalence varies dramatically from region to region, particularly between developed 
countries with rates between 25 to 50%, and developing countries with rates as high as 70 
to 90% (26, 28). 
A general review of studies on the epidemiology of H. pylori infection in China 
determined the prevalence of infection to be 61% (29). A more specific study analyzing 
65 Chinese counties found H. pylori seropositivity rates of 65% (range 28 - 94%) in 
northern counties and 57% (range 29 - 96%) in southern counties (30). One study 
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analyzing a specific southern China county found the prevalence of H. pylori infection to 
be 80%. Interestingly, this study found a prevalence of only 58% in Hong Kong which 
was comparable to a previous study (prevalence of 55%) (31, 32, 33). (Note that although 
the prevalence for Hong Kong was lower than southern China, it is still significantly 
higher than other developed countries.) 
Furthermore, these rates are comparable to Chinese populations found in other 
areas of Asia. A study carried out in Malaysia, a country with large Chinese and Indian 
populations, found the prevalence in the Chinese cohort to be 49%. In contrast, the 
prevalence of infection among the Malay and Indian populations was 16% and 62%, 
respectively (34). 
Risk Factors for Infection 
The incidence of H. pylori infection among adults is low, estimated between 1% 
per year in developed countries and 3% per year for developing countries (22). Childhood 
appears to be the dominant time period for acquiring H. pylori (22, 26). Prevalence, 
however, varies considerably among children in different regions; it appears that 
acquisition is low in the children of developed countries, while in the developing world 
this age group represents the major period of new infection (22). It has been hypothesized 
that an ‘environmental pool’ of H. pylori exists to which children are exposed in 
developing countries; in developed countries this source has either been eliminated or 
children are not exposed to it. Either possibility is believed secondary to improvements in 
sanitation, refrigeration and water purification. Consequently, adults more than 50 years 
of age in developed countries maintain a high prevalence of infection (probably acquired 
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in childhood), while prevalence is low among children in developed countries. The 
present positive correlation between age and prevalence of infection is thought to be due 
to a birth cohort effect (26). 
Notable correlations do exist across all ages in which indirect relationships for 
both socioeconomic status and education level and H. pylori infection have been shown; 
other potential risk factors such as gender and alcohol use have been investigated, but 
display no consistent relationship with prevalence. Interestingly, gastroenterologists and 
endoscopists have been shown to display increased seropositivity for H. pylori (22). 
Treatment 
Despite mounting evidence supporting H. pylori's role in causing peptic ulcer 
disease, many clinicians remained skeptical. It was not until February 1994 that the 
National Institutes of Health convened a Consensus Development Conference Panel 
which reviewed contemporary Helicobacter pylori research and concluded that peptic 
ulcer disease was often an infections disease and should be treated as such. 
Active H. pylori infection has been shown to be effectively treated by several 
treatment protocols. The most successful in the U.S. consist of two weeks of acid 
suppression combined with at least two antibiotics. The most popular combinations use a 
proton pump inhibitor with either amoxicillin and a macrolide (typically clarithromycin) 
or with a nitroimidazole (typically metronidazole) and a macrolide (35). These treatment 
protocols cure H. pylori in 85 to 95% of patients enrolled in Western studies (36). Since 
the outcome of therapy is probably dependent in part on antibiotic resistance, these rates 
may differ in Asia due to the significantly higher levels of metronidazole resistance 
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present there. For all strains of H. pylori, levels of metronidazole resistance as high as 
50% have been reported in Hong Kong and Singapore (80 to 90% levels of resistance 
were reported in India) (37). 
In the future, therapy for H. pylori may consist of vaccination. Current efforts in 
mice have succeeded in producing vaccines that not only prevent infection, but also cure 
preexistent H. pylori infection. However, these vaccines, which use a H. pylori urease, 
cannot yet be applied to humans since they require an adjuvant detrimental to humans, 
such as cholera toxin. A more efficacious vaccine may result from efforts to utilize H. 
pylori outer membrane proteins (OMPs), such as porins, to produce an effective immune 
response (36). 
Eradication 
Although H. pylori is the most common chronic bacterial infection in humans 
with definite links to gastrointestinal pathology, most infected people never display 
clinical signs or symptoms of disease (27). Consequently, arguments have been made for 
and against widespread vaccination or eradication of this organism and whether 
eradication would be cost effective (38, 39). Some studies have even suggested a 
beneficial role for H. pylori in protecting against gastroesophageal reflux disease (GERD) 
(40, 41) and possibly a secondary protection from the GERD-induced esophageal cancer. 
Yet, in patients with PUD, eradication of H. pylori decreases the recurrence rate of PUD 
to 4%, from 80% (or 25% if on long-term histamine-2 (H2) receptor blockers). 
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Diagnostic Tests for Infection 
As awareness of the role of H. pylori in gastroduodenal diseases has increased, 
many patients have sought testing and treatment from their primary care physicians. 
Invasive biopsy-based tests, including culture, histology and the rapid urease test, are 
effective in diagnosing H. pylori infection. However, considerable investments in 
facilities, equipment, expertise and time are required to perform these tests. Invasive tests 
are not a practical option for the primary care setting in which testing is performed at the 
site. 
Non-invasive tests are attractive for this setting in that they do not have many of 
these requirements. Additionally, non-invasive tests eliminate the potential for sampling 
error of the biopsy-based tests due to the patchy distribution of H. pylori in some patients. 
In fact, screening young dyspeptic patients for H. pylori by non-invasive tests such as 
serology has been shown to reduce the need for endoscopy by up to 30% without missing 
significant disease in Western countries (42, 43, 44) and economic modeling suggests this 
strategy is cost effective (45). Still, conventional non-invasive tests such as serum 
enzyme-linked immunosorbent assays (ELISA) and urea breath tests also require 
laboratory support which itself is not widely available in primary care settings. 
Commercial rapid whole blood tests for H. pylori have been introduced in recent 
years. These tests do not require separation of serum, and results are available within 
minutes without the need of laboratory assistance. It is important to note that these near¬ 
patient rapid whole blood tests, unlike ELISA assays, are qualitative tests. Still, 
preliminary studies found these commercial kits may be as accurate as laboratory-based 
serology tests (46, 47, 48), when tested in Western populations. 

Due to the antigenic heterogeneity of H. pylori, the performance of commercial 
serology tests varies considerably among different populations (49, 50). To date, most 
published data have been based on Western populations (46, 47, 48, 51, 52, 53, 54, 55, 
56, 57, 58). Whether these results can be reproduced in Asians remains unknown. 
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Statement of Purpose and Hypothesis 
The aim of this study was to assess the performance of the rapid whole blood test, 
FlexPack HP (Abbott Laboratories, North Chicago, Illinois), in Chinese patients with 
dyspepsia. It was our hypothesis that the Abbott FlexPack HP Test for IgG antibodies to 
Helicobacter pylori infection in whole blood is accurate for diagnosing H. pylori 
infection in Chinese (specifically Hong Kong Chinese) patients with clinical signs and 
symptoms of upper gastrointestinal tract disease. 
- 
10 
Materials and Methods 
Location of Study 
This study was carried out at the Prince of Wales Hospital in Hong Kong, China. 
Prince of Wales Hospital, the first fully air-conditioned Government hospital in Hong 
Kong, was officially opened in 1984. Located in the city center of Shatin, it is an acute 
general hospital as well as the teaching hospital of the Medical Faculty of the Chinese 
University of Hong Kong. With more than 1,400 beds and a total workforce of over 
4,000, it is the regional hospital of the Eastern New Territories serving the population of 
Shatin, Tai Po, Northern New Territories, Sai Kung and the outlying islands (59). 
Protocol 
Consecutive patients about to undergo esophagogastroduodenoscopy to evaluate 
dyspepsia were considered for enrollment between June 17, 1997 and August 6, 1997. 
My goal was to enlist 100 patients, a sample size selected arbitrarily. Exclusion criteria 
were age less than 18 years, previous treatment for H. pylori, previous gastric surgery, 
and current use of antibiotics, proton pump inhibitors, or H2 receptor blockers. Informed 
verbal consent was obtained from all subjects by research nurses. All patients underwent 
endoscopy (Olympus XQ-200; Olympus, Tokyo, Japan) with biopsy in the Endoscopy 
Center at Prince of Wales Hospital, performed by the center’s staff physicians. Three 
antral and two body biopsy samples were taken from the stomach: one antral biopsy was 
used for rapid urease testing and the remaining four biopsies were sent for histological 
evaluation. The rapid urease test (CLOtest, Delta West, Bentley, Australia) was 
performed at room temperature and was considered negative if no colorimetric change 
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occurred within 24 hours. Specimens destined for histologic inspection were placed in 
10% formalin, transported to the hospital’s pathology department and subsequently 
stained with hematoxylin and eosin. The hospital’s staff pathologists detennined 
histological diagnosis. 
All patients also underwent f13C] urea breath testing (UBT) at least two hours 
after endoscopy. UBT’s were perfonned either by a research nurse or by myself; the 
laboratory analyzed all results. Following a previously described method (60) the fasting 
patient first drank a test meal consisting of a 200 ml concentrated citrate solution to delay 
gastric emptying. Following a two-minute delay, three baseline breath samples were 
collected. Samples were obtained by having the patient blow through a straw resting 
inside of a 10ml test tube. The straw was slowly withdrawn from the tube over 
approximately a four-second period until a blush of condensation appeared, immediately 
after which the tube was capped. After an eight-minute delay, the patient swallowed a 
lOOmg [l3C] urea tablet (Cambridge Isotope Laboratories Inc., Andover, Massachusetts) 
dissolved in 25ml of water, followed by a 25ml drink of water alone. The patient then 
performed one minute of exercise including deep waist bends to encourage sample 
mixing. After 30 minutes, three additional breath samples were obtained from the 
patients in the previously described fashion. All samples were covered with Parafilm 
until analyzed via mass spectrometry (Europa scientific 20:20 Isotope Ratio Mass 
13 12 Spectrometer with a RoboPrep G Automatic Breath Sampler). The C/ C ratio of the 
sample was calculated by the computer against the known isotopic ratio of the reference 
gas. The l3C/12C isotopic ratios were reported in the per ml format: delta 13C/ml = 
(((l3C/12C sample)-!) X IOOO)/(13C/l2C Standard). Excess l3C was calculated as the 
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difference between the baseline delta l3C and 30 minute delta l3C (30-minute delta l3C 
baseline l3C). Values greater than or equal to 3.5 were considered to be positive. 
Patients with concordant histology and CLOtest results, but a discordant UBT result 
returned for a second UBT which was used as the final UBT result in all cases. 
Patients were tested for H. pylori on the day of their endoscopy using the 
FlexPack HP rapid whole blood serology test kit (manufactured by SmithKline 
Diagnostics, Inc. for Abbott Laboratories, Abbott Park, Illinois). I performed all FlexPack 
HP tests. The FlexPack HP test incorporates high molecular weight cell-associated 
proteins as the antigen to detect H. pylori-specific IgG antibodies in whole blood. 
FlexPack HP test cards ready for study were kept at room temperature (no more than 30 
days), opened within minutes of use and were prepared according to the manufacturer’s 
specifications. After venipuncture, blood was immediately transferred from the syringe 
into EDTA and soybean extract-coated mini-pipets included in the test kit and directly 
applied to the appropriate chromatography column on the prepared test card. Following 
the flow of the sample through this initial column to its termination point, the test card 
was closed and the time was noted. After exactly four minutes the results were read in the 
card’s test window. Within the test window the appearance of two distinct lines was 
treated as positive, a single control line represented a negative result, and the absence of 
any line indicated an invalid test. Any trace of a line in the expected positive position was 
regarded as a positive result per product instructions. I read all the rapid whole blood test 
results without knowledge of the endoscopy findings, or results from other H. pylori tests. 
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Data Analysis 
The “gold standard” used to determine H. pylori infection was defined prior to 
analysis as positive results of at least two of the three reference tests performed to 
diagnose H. pylori infection (histology, CLOtest and UBT). I calculated sensitivity, 
specificity and positive and negative predictive values for the FlexPack HP with 95% 
confidence intervals using formulas created within Microsoft Excel 97 (Microsoft, 
Redmond, Washington) and using the Java based internet site “2-way Contingency Table 
Analysis,” (61). Unpaired Ttests (mean comparison) and Z-tests (proportion comparison) 
were performed using the internet sites “r test: Independent Groups,”(62) and “WebStat- 
Proportions (p statistics): Two sample,” respectively (63). A P value of 0.05 was 
considered statistically significant. Data are summarized as mean +/- standard deviation. 
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Results 
Patient Characteristics 
Characteristics of 100 patients from Hong Kong undergoing upper GI tract 
endoscopy for dyspepsia are displayed in Table 1. One hundred patients (55 female, 45 
male) were studied. The patients' mean age was 51 +/- 15 years (range, 21 to 90 years). 
Fifty-eight patients (58%) were older than 45 years of age. Seventeen (17%) patients had 
a history of peptic ulcer disease. At esophagogastroduodenoscopy, five (5%) patients had 
gastric ulcers, six (6%) had duodenal ulcers, seven (7%) had gastric erosions and 20 
(20%) had gastric erythema. In the remaining 62 patients, no endoscopically apparent 
disease was found. No patients had duodenitis or duodenal erosions. 
Characteristics of H. pylori prevalence in the 100 patients studied are given in 
Table 2. Fifty-four (54%) patients were confirmed to be H. pylori positive based on at 
least two positive results among the reference tests (rapid urease test, histology, and [l3C] 
urea breath test). The H. pylori-positive group had a mean age (51 +/- 15 years) similar to 
the H. pylori-negative group (52 +/- 16). There was no statistically significant difference 
in prevalence of infection between men and women (55% vs. 53%, respectively [P = 
NS]). 
The prevalence of H. pylori was highest among the six patients with duodenal 
ulcers and the five patients with gastric ulcers (83% and 80% respectively). The 
prevalence among the 20 patients with gastric erythema was 60%. Thirty of the 62 
patients with no apparent disease (49%) were H. pylori positive and three of seven 
patients (43%) with gastric erosions were positive for H. pylori. Note that the prevalence 
of H. pylori in the group with ulcers, nine of eleven patients (82%), was significantly 
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different from the prevalence in the group without ulcers, 45 of 89 patients (51%) (P = 
0.05). 
Diagnosis of H. pylori Infection - Reference Panel Analysis 
The relationship between reference test and FlexPack HP test results in each of 
the 100 patients are presented in Table 3. Concordance of all test results (including the 
FlexPack HP) occurred in 74 of the 100 patients. Reference tests alone were concordant 
in 89 of the 100 patients; in 11 patients, reference tests were discordant. 
Each reference test method was discordantly positive or negative in at least one 
patient. Three of the 54 “//. /^/on-positive” patients tested negative for infection by 
histology, two patients by UBT and one patient by CLOtest. Three of the 46 “//. pylori- 
negative” patients tested positive for infection by UBT, and two by histology. 
Diagnosis of H. pylori Infection - FlexPack HP Test Performance 
The sensitivity, specificity, positive and negative predictive values for the 
FlexPack HP are 82%, 85%, 86% and 80% respectively (see Table 4). Also shown on 
Table 4 are values for FlexPack HP’s performance in the age groups less than or equal to 
45, greater than 45, less than or equal to 65 and greater than 65 years of age; no 
statistically significant differences occurred in any of the characteristics between the age 
groups. Poor readability, manifested as faintly positive results, occurred in 15 FlexPack 
HP observations (15%). All tests were valid based on performance of built-in positive 
controls. However, one of the 51 positive FlexPack HP observations and three of the 49 
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negative observations displayed faint positive control lines. None of the tests with faint 
positive control lines displayed discordant results from the defined gold standard. 
Among the nine patients with H. pv/or/'-associated peptic ulcers, false-negative 
serology was encountered in two of the four (50%) patients with gastric ulceration. No 
false-negative FlexPack FIP results occurred in the five patients with H. py/oz-z-associated 
duodenal ulceration or in the three patients with H. pylori-associated gastric erosion. 
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Discussion 
In 1994, the National Institutes of Health Consensus Development Panel on H. 
pylori recommended eradication of H. pylori infection in all infected patients with active 
peptic ulcer disease or with a history of PUD and on maintenance acid suppression. Tests 
for diagnosing Helicobacter pylori infection which are simple, accurate and rapid are 
needed in the near-patient setting to facilitate the diagnosis and treatment of H. pylori. In 
fact, the American Gastroenterological Association’s 1998 medical position statement for 
evaluation of dyspepsia specifically recommended that “a locally validated noninvasive 
H. pylori test (e.g., serology or urea breath test) is undertaken to detennine if the patient 
is infected” for patients under 46 years of age without alarm features or previous 
investigations (64). A European H. pylori study group developed similar 
recommendations (65). 
Guidelines for the Asian Pacific region, following the initiatives of the West, were 
formulated in 1997. Unique characteristics of this population include the high 
background prevalence of infection, high rates of gastric cancer, and limited resources in 
the medical community. Non-endoscopic methods were deemed acceptable for this 
region as diagnostic tests for H. pylori infection, including the UBT or a locally validated 
antibody test (66). Clinicians in Hong Kong, being members of this region, played a 
major role in formulating these guidelines. 
In previous studies, prevalence of H. pylori infection in Hong Kong was 55 
58%, a rate comparable to the value of 54% found in the present analysis. Although Hong 
Kong is a developed country, its population displays a high H. pylori prevalence, even in 
younger age groups. For example, the 21 to 30 year age group in previous studies 
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displayed a prevalence of 53%, while our study determined a value of 52% for those no 
older than 45 years of age (31, 32, 33). (The 21 to 30 year age group in our study 
consisted of only eight members, however, 50% were positive for H. pylori infection.) 
The analysis of H. pylori prevalence in relation to endoscopic diagnoses in this 
study is also similar to previous studies. While the number of cases are low in each 
diagnostic category (see Table 1), values of 48%, 80% and 83% prevalence were found 
for no apparent disease, gastric ulcer and duodenal ulcer patients, respectively. These 
values compare to those from native Southern Chinese patients of 45%, 76% and 75%, 
respectively. In studies highlighting Hong Kong Chinese, duodenal ulcer was noted to be 
positive for H. pylori in excess of 90% (67). 
Considering the extent of the problem of H. pylori infection in the Hong Kong 
Chinese population, a comprehensive plan was required to diagnose and treat positive 
cases. As noted earlier, an antibody test was deemed acceptable for this population if 
locally validated. Most serology studies prior to this, however, were earned out in 
Western populations and few had previously assessed whole blood serology tests. 
Subsequent studies have shown commercial rapid whole blood serology tests to be 
adequately accurate and potentially useful for in-office H. pylori testing if clinicians are 
aware of the limitations of the tests (68, 69). Clinicians must remember that these tests 
can only indicate the presence of specific IgG antibodies to H. pylori, but do not 
distinguish between current and past H. pylori infection; furthermore, a negative test may 
indicate that H. pylori antibodies either are not present or are present at levels too low for 
detection, as may be the case early in infection. Although these near-patient, rapid whole 
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blood tests appeared appropriate for the needs of the Hong Kong Chinese population, 
they required local validation. 
This is the first analysis of a rapid whole blood test for H. pylori in the Hong 
Kong Chinese population. In this study, the overall performance of the FlexPack HP test 
in Hong Kong Chinese patients was comparable to Western results for other commercial 
serology kits. Our study determined a sensitivity of 82% (Cl 73 - 88%) and a specificity 
of 85% (Cl 74 - 92%) for the FlexPack HP which compares favorably to sensitivities of 
83 to 96% and specificities of 70 to 93% from the West (46, 47, 48, 51, 52, 53, 54, 55, 56, 
57, 58). 
Previously, discrepancies between Western and Asian populations in the 
performance of commercial serology tests for H. pylori were reported (49, 58, 70). A 
study from Thailand showed that a commercial ELISA (Pylori Stat; BioWhittaker, 
Walkerville, Maryland) was inferior to an ELISA developed from local H. pylori strains 
(49). Prior experience at Prince of Wales Hospital with commercial ELISAs in a group of 
Chinese patients was also disappointing (70). The performance of another rapid whole 
blood serology test, the Helisal One-Step, was recently evaluated between two groups of 
European and South Asian patients in a study from Britain (58). The authors reported 
unexpectedly poor results in Asian patients (sensitivity, 79 to 81% versus 93 to 96%; 
specificity, 42 to 50% versus 57 to 64%). 
The reasons for these earlier discrepant results are unclear. Poor sensitivity in 
prior comparisons is possible if antibody is absent, in a concentration too low to detect, or 
non-reactive to the antigen in the assay. In earlier studies, poor sensitivity may be 
accounted for by the considerable antigenic heterogeneity of H. pylori. By using bacterial 
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isolates and sera from different continents, Hook-Nikanne et al. demonstrated that 
antigens prepared from individual bacterial strains obtained from North America and 
China were not sensitive enough for serological detection of H. pylori in a heterogeneous 
population (50). This phenomenon may be overcome by using pools of bacterial strains 
obtained from different ethnic groups. If the patented antigen utilized in the FlexPack HP, 
high molecular weight cell-associated proteins (HM-CAP™), is of the pooled type, it 
could explain the comparable sensitivity realized in this study. 
Our study also demonstrated specificity for FlexPack HP comparable to Western 
analyses. Poor specificity in previous comparisons may be accounted for by the high 
carriage of other cross-reacting intestinal pathogens in developing countries, such as 
Campylobacter species, which may produce false-positive serological results (46). This 
problem is less likely with FlexPack HP since it has been previously shown to have no 
cross reactivity with a number of bacteria, including Campylobacter jejuni, 
Campylobacter fetus, Campylobacter coli, Escherichia coli, and Helicobacter mustalae 
(71). An alternate explanation involves the inadvertent use of antibiotics for respiratory 
and intestinal infections in the community which may inhibit or even eradicate H. pylori. 
Since antibody can persist in serum for months after eradication, serological results may 
be falsely-positive after eradication and contribute to decreased test specificity. Previous 
studies may not have controlled for this possibility. The present study excluded patients 
previously treated for H. pylori or currently using antibiotics. 
In North America and Europe, the test-and-treat strategy has been adopted for the 
management of dyspepsia (64, 65). Serology, being more widely accessible than the urea 
breath test, is likely to become more popular for this purpose. Our study found overall 
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sensitivity and specificity to be similar to that for series carried out in the West. A study 
in a larger population of Hong Kong Chinese less than 45 years of age may be 
appropriate before this serology kit is used in test-and-treat protocols in this age group. 
Furthermore, our analysis found that 50% of H. /?v/on'-associated gastric ulcers (two of 
four gastric ulcer patients, or two of nine [22%] peptic ulcer patients overall) would have 
been missed had endoscopy been withheld in these patients with negative rapid whole 
blood serology tests. Lastly, the risk of missing young patients with gastric cancer has not 
yet been considered. 
In conclusion, the FlexPack HP is quick and convenient to use and performed 
adequately in a secondary care setting in Hong Kong Chinese patients. This test may be 
useful for in-office H. pylori testing if clinicians are aware of the limitations of the test. 

22 
Acknowledgments 
I thank Dr. Matthew Cohen for his guidance and assistance in preparing this 
manuscript. I also thank Dr. Joseph J. Y. Sung for his supervision and for providing me 
the opportunity to perform this study in his Department at the Prince of Wales Hospital, 
Hong Kong. I am grateful to Dr. Wai K. Leung for his thoughtful analysis. 1 am also 
grateful to Megan Lisska for her insight and for her overall encouragement along the 
way. I am indebted to the members of the Endoscopy Center community at Prince of 
Wales Hospital, particularly to Roamy Suen and Jessica Ching. Finally, I thank the Yale 
University Council on East Studies for its support of my project through the Charles Kao 
Grant. 

23 
References 
1. Marshall, B.J., Warren, J.R. 1984. Unidentified curved bacilli in the stomach of 
patients with gastritis and peptic ulceration. Lancet. 1(8390): 1311-1315. 
2. Farthing, M.J.G. 1998. Helicobacter pylori infection: an overview. Br Mecl J. 54( 1): 1 - 
6. 
3. Buckley, M.J.M., O’Morain, C.A. 1998. Helicobacter biology - discovery. Br Med J. 
54( 1 ):7-16. 
4. Marshall, B.J., Warren, J.R. 1983. Unidentified curved bacilli on gastric epithelium in 
active chronic gastritis. Lancet. 1:1273-1275. 
5. Marshall, B.J., Armstrong, J.A., McGechie, D.B., Glancy, R.J. 1985. Attempt to fulfil 
Koch's postulates for pyloric Campylobacter. Med J Aust. 142(8):436-439. 
6. Rauws, E.A., Langenberg, W., Houthoff, H.J., Zanen, H.C., Tytgat, G.N. 1988. 
Campylobacterpyloridis-associaied chronic active antral gastritis. A prospective study of 
its prevalence and the effects of antibacterial and anti ulcer treatment. Gastroenterology. 
94(1 ):33-40. 
7. Peterson, W.L. 1991. Helicobacter pylori and peptic ulcer. N Engl J Med. 324:1043- 
1048. 
8. Rauws, E.A., Tytgat, G.N. 1990. Cure of duodena ulcer associated with eradication of 
Helicobacter pylori. Lancet. 335:1233-1235. 
9. Nomura, A., Stemmermann, G.N., Chyou, P.H., Kato, I., Perez-Perez, G.I., et al. 1991. 
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in 
Hawaii. N Engl J Med. 325(16): 1132-1136. 
10. Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Chang, Y., Vogelman, J.H., et al. 
1991. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 
325(16): 1127-1131. 
11. Wotherspoon, A.C., Doglioni, C., Diss, T.C., Pan, L., Moschini, A., et. al. 1993. 
Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated 
lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 342(8871 ):575- 
577. 
12. Wotherspoon, A.C., Ortiz-Hidalgo, C., Falzon, M.R., Isaacson, P.G. 1991. 
Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 
338(8776):! 175-1176. 

13. McCarthy, C., Patchett, S., Collins, R.M., Beattie, S., Keane, C., et al. 1995. Long¬ 
term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci. 
40(1 ):114-119. 
14. Gasbarrini, A., De Luca, A., Fiore, G., Gambrielli, M., Franceschi, F., et. al. 1998. 
Beneficial effects of Helicobacter pylori eradication on migraine. 
Hepatogastroenterology. 45(21 ):765-770. 
15. Jacoby, E.B., Porter, K.B. 1999. Helicobacter pylori infection and persistent 
hyperemesis gravidarum. Am J Perinatol. 16(2):85-88. 
16. Frigo, P., Lang, C., Reisenberger, K., Kolbl, H., Hirschl, A.M. 1998. Hyperemesis 
gravidarum associated with Helicobacter pylori seropositivity. Obstet Gynecol. 
91 (4):615-617. 
17. Mendall, M.A., Goggin, P.M., Molineaux, N., Levy, J., Toosy, T., et. al. 1994. 
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 
71 (5 ):437-439. 
18. Patel, P., Mendall, M.A., Khulusi, S., Northfield, T.C., Strachan, D.P. 1994. 
Helicobacter pylori infection in childhood: risk factors and effect on growth. Br Med J. 
309(6962):1119-1123. 
19. Patchett, S.E. 1998. Helicobacter pylori eradication cost-benefit: the case against. Br 
MedJ. 54(1 ):251-257. 
20. Lyon:IARC. 1994. International Agency for Research on Cancer. Schistosomes, liver 
flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic 
Risk to Humans. Vol 6. 
21. Atherton, J.C. 1998. H. pylori virulence factors. Br Med J. 54(1): 105-120. 
22. Feldman, R.A., Eccersley, A.J., Hardie, J.M. 1998. Epidemiology of Helicobacter 
pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br 
MedJ. 54(l):39-53. 
23. Akamatsu, T., Tabata, K., Hironga, M., Kawakami, H., Uyeda, M. 1996. 
Transmission of Helicobacter pylori infection via flexible fiberoptic endoscopy. Am J 
Infect Control. 24(5):396-401. 
24. Grubel, P., Hoffman, J.S., Chong, F.K., Burstein, N.A., Mepani, C., et. al. 1997. 
Vector potential of houseflies (Musca domestica) for Helicobacter pylori. J Clin 
Microbiol. 35(6):1300-1303. 

25 
25. Leung, W.K., Sung, J.J., Ling, T.K., Siu, K.L., Cheng, A.F. 1999. Use of chopsticks 
for eating and Helicobacter pylori infection. Dig Dis & Sci. 44(6): 1173-1176. 
26. Cave, D.R. 1997. How is Helicobacter pylori transmitted? Gastroenterology. 113(6 
Suppl):S9-14. 
27. Anonymous. 1997. The report of the Digestive Health Initiative SM International 
Update Conference on Helicobacter pylori. Gastroenterology>. 113(6 Suppl):S4-8. 
28. Dunn, B.E., Cohen, H., Blaser, M.J. 1997. Helicobacter pylori. Clin Microbiol Rev. 
10(4):720-741. 
29. Zhou, D., Yang, H. 1995. Epidemiology of Helicobacter pylori infection in the 
People's Republic of China. Chin MedJ. 108(4):304-313. 
30. Chen, J.S., Campbell, T.C., Li, J.Y., Peto, R. Diet, life-style and mortality in China. A 
study of the characteristics of 65 Chinese counties. Oxford University Press, Oxford, 
U.K. 
31. Wong, B.C., Lam, S.K., Ching, C.K., Hu, W.H., Kwok, E. et al. 1999. Differential 
Helicobacter pylori infection rates in two contrasting gastric cancer risk regions of South 
China. China Gastric Cancer Study Group. J Gastroenterol Hepatol. 14(2): 120-125. 
32. Chan, G.S., Yuen, S.T., Chu, K.M., Ho, J.W., Leung, S.Y., et. al. 1999. Helicobacter 
pylori in Meckel's diverticulum with heterotopic gastric mucosa in a population with 
relatively high H. pylori prevalence rate. J Gastroenterol Hepatol. 14(4):313-316. 
33. Ching, C.K., Yuen, S.T., Luk, I.S.C., Ho, J., Lam, S.K. 1994. The prevalence of 
Helicobacter pylori carrier rates among the healthy blood donors in Hong Kong. Journal 
of the Hong Kong Medical Association. 46:295-298. 
34. Goh, KL. 1997. Prevalence of and risk factors for Helicobacter pylori infection in a 
multi-racial dyspeptic Malaysian population undergoing endoscopy. J Gastroenterol 
Hepatol. 12(6):S29-35. 
35. Lind, T., Megraud, F., Bardhan, K.D. 1997. The MACH2 study: antimicrobial 
resistance in Helicobacter pylori therapy - the impact of omeprazole. Gut. 41(suppl 
1 ):A89. 
36. Axon, A.T.R. 1998. Treatment of Helicobacter pylori: future therapeutic and 
prophylactic perspectives. Gut. 43(suppl 1):S70-S73. 
37. Fock, K.M. 1997. Peptic ulcer disease in the 1990s: an Asian perspective. J 
Gastroenterol Hepatol. 12(6):S23-28. 
38. Moayyedi, P., Axon, A.T. 1998. Is there a rationale for eradication of Helicobacter 
pylori? Cost-benefit: the case for. BrMedJ. 54(1 ):243-250. 

26 
39. Patchett, SE. 1998. Helicobacter pylori eradication cost-benefit: the case against. Br 
Med J. 54( 1 ):251 -257. 
40. Wu, J.C., Sung, J.J., Ng, E.K., Go, M.Y., Chan, W.B. et al. 1999. Prevalence and 
distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the 
East. Am J Gastroenterol. 94(7): 1790-1794. 
41. Labenz, J., Blum, A.L., Bayerdorffer, E., Meining, A., Stolte, M. et. al. 1997. Curing 
Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux 
esophagitis. Gastroenterology. 112(5): 1442-1447. 
42. Sobala, G.M., Crabtree, J.E., Pentith, J.A., Rathbone, B.J., Shallcross, T.M., et al. 
1991. Screening dyspepsia by serology to Helicobacter pylori. Lancet. 338:94-96. 
43. Mendall, M.A., Goggin, P.M., Marrere, J.M. 1992. Helicobacter pylori screening 
prior to endoscopy. Ear J Gastroenterol Hepatol. 4:713-717. 
44. Patel, P., Khulisi, S., Mendall, M.A., Lloyd, R., Jazrawi, R, et al. 1995. Prospective 
screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 346:1315-1318. 
45. Fendrick, A.M., Chemew, M.E., Hirth, R.A. 1996. Bloom BS. Immediate endoscopy 
or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: 
estimating cost-effectiveness using decision analysis. Yale J Biol Med. 69(2):187-195. 
46. Graham, D.Y., Evans, D.J., Peacock, J., Baker, J.T., Schrier, W.H. 1996. Comparison 
of rapid serological tests (FlexSure HP and QuickVue) with conventional ELISA for 
detection of Helicobacter pylori infection. Am J Gastroenterol. 91 (5 ):942-948. 
47. Enroth, H., Rigo, R., Hulten, K., Engstrand, L. 1997. Diagnostic accuracy of a rapid 
whole-blood test for detection of Helicobacter pylori. J Clin Microbiol. 35:2695-2697. 
48. Jones, R., Philips, I., Felix, G., Tait, C. 1997. An evaluation of near-patient testing for 
Helicobacter pylori in general practice. Aliment Pharmacol Ther. 11:101 -105. 
49. Bodhidatta, L., Hoge, C.W., Chumratanakul, S., Nirknoy, W., Sampathanukul, P. et. 
al. 1993. Diagnosis of Helicobacter pylori infection in a developing country: comparison 
of two ELISAs and a seroprevalence study. J Infect Dis. 168:1549-1553. 
50. Hook-Nikanne, J., Perez-Perez, G.I., Blaser., M.J. 1997. Antigenic characterization of 
Helicobacter pylori strains from different parts of the world. Clin Diagn Lab Immunol. 
4:592-597. 
51. Anderson, J.C., Cheng, E., Roeske, M., Marchildon, P., Peacock, J., et. al. 1997. 
Detection of serum antibodies to Helicobacter pylori by an imniunochromatographic 
method. Am J Gastroenterol. 92:1135-1139. 

27 
52. Duggan, A., Logan, R., Knifton, A., Logan, R. 1996. Accuracy of near-patient blood 
tests for Helicobacter pylori. Lancet. 348:617. 
53. Elitsur, Y., Neace, C., Triest., W.E. 1997. Comparison between a rapid office-based 
and ELISA serological test in screening for Helicobacter pylori in children. Helicobacter. 
2(4): 180-184. 
54. Kroser, J.A., Faigel, D.O., Furth, E.E., Metz, D.C. 1998. Comparison of rapid office- 
based serology with formal laboratory-based ELISA testing for diagnosis of Helicobacter 
pylori gastritis. Dig Dis Sci. 43:103-108. 
55. Moayyedi, P., Cater, A.M., Catto, A., Heppell, R.M., Grant, P.J., et. al. 1997. 
Validation of a rapid blood test for diagnosing Helicobacter pylori infection. Br Med J. 
314:119. 
56. Mowat, C., Murray, L., Hilditch, T.E., Kelman, A., Oien, K., et. al. 1998. 
Comparison of Helisal rapid blood test and l4C-urea breath test in determining 
Helicobacter pylori status and predicting ulcer disease in dyspeptic patients. Am J 
Gastroenterol. 93:20-25. 
57. Schrier, W.H., Schoenglod, R.J., Baker, J.T., Norell, J.L., Jaseph, C.L., et. al. 1998. 
Development of FlexSure HP—an immunochromatographic method to detect antibodies 
against Helicobacter pylori. Clin Chem. 44:293-298. 
58. Stone, M.A., Mayberry, J.F., Wicks, A.C., Livsey, S.A., Stevens, M., et. al. 1997. 
Near patient testing for Helicobacter pylori: a detailed evaluation of the Cortecs Helisal 
Rapid Blood test. Eur J Gastroenterol Hepatol. 9:257-260. 
59. Prince of Wales Hospital, Hong Kong Internet HomePage. Available at: http:// 
www.ha.org.hk/pwh/greeting.html. Accessed on January 11, 2000. 
60. Logan, R.P.H. 1991. The European Standard 13C Urea Breath Test for the detection of 
Helicobacter pylori. Eur J of Gastroenterol and Hepatol. 3:915-921. 
61. 2-way Contingency Table Analysis. Available at: http://members.aol.com/johnp71/ 
ctab2x2.html. Accessed on January 11, 2000. 
62. t test: Independent Groups, http://www.assumption.edu/html/academic/users/avadum/ 
applets/ttest/ttest.html. Accessed on January 11, 2000. 
63. WebStat-Proportions (p statistics): Two sample, http://www.stat.sc.edu/webstat/ 
version2.0/stat/TwoSampleP.html Accessed on February 17, 2000. 

28 
64. American Gastroenterological Association. 1998. American Gastroenterological 
Association medical position statement: evaluation of dyspepsia. Gastroenterology’. 
114:579-581. 
65. European Helicobacter pylori Study Group. 1997. Current European concepts in the 
management of Helicobacter pylori infection. The Maastricht consensus report. Gut. 
41:8-13. 
66. Lam, S.K., Talley, N.J. 1998. Report of the 1997 Asia Pacific Consensus Conference 
on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 13(1): 1 - 
12. 
67. Lam, S.K., Wong, B.C. 1998. Helicobacter pylori, peptic ulcer and gastric cancer in 
China. Yale J Biol Med. 71 (1): 1 -6. 
68. Sadowski, D., Cohen, El., Laine, L., Greenberg, P., Goldstein, J., et al. 1998. 
Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter 
pylori infection. Am J Gastroenterol. 93(11 ):2119-2123. 
69. Chey, W.D., Murthy, U., Shaw, S., Zawadski, A., Montague J., et al. 1999. A 
comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori 
infection: a United States, multicenter trial. Am J Gastroenterol. 94(6): 1512-1516. 
70. Leung, W.K., Ng, E.K.W., Sung, J.Y. 1998. Performance of commercially available 
serological ELISA test for H. pylori infection: discrepancy between East and West. 
Gastroenterologyk 114: A201. 
71. FlexPack HP Product Instructions. Data on file, SmithKline Diagnostics, Inc. 

29 
Table 1. Characteristics of 100 Consecutive Patients From Hong Kong Who Had Esophago- 
gastroduodenoscopy to Evaluate Dyspepsia 
Age 51 +/- 15 years a 
Gender 
Female 55% 
Male 45% 
Prior ulcer disease 17% 
Endoscopic diagnosis 
No apparent disease 62% 
Gastric erythema 20% 
Gastric erosion 7% 
Duodenal ulcer 6% 
Gastric Ulcer 5% 
Mean +/- standard deviation 
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Table 2. Characteristics of H. pylori Prevalence in 100 Patients From Hong Kong Who 
Had Esophagogastroduodenoscopy to Evaluate Dyspepsia " 
Age 
H. pylori-positive group (n = 54) 51 +/- 15 years h 
H. pylori- negative group (n = 46) 52 +/- 16 years 
Overall H. pylori prevalence 54% 
H. pylori prevalence for endoscopic diagnosis 
Duodenal ulcer (n = 5) 83% 
Gastric ulcer (n = 4) 80% 
Gastric erythema (n = 12) 60% 
Gastric erosion (n = 3) 43% 
No apparent disease (n = 30) 48% 
“ Patients were confirmed to be H. pylori positive based on at least two positive results among the 
reference tests: rapid urease test, histology, and [1 3C] urea breath test. 
h Mean +/- standard deviation 
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Table 3. Relationship Between Reference Test Results and FlexPack HP Results Among 100 
Patients With Dyspepsia From Hong Kong “ 
Number of Reference Tests Positive 
0 1 2 3 
FlexPack HP Positive 6 1 5 39 
FlexPack HP Negative 35 4 1 9 
Total 41 5 6 48 
n Patients were confirmed to be H. pylori positive based on at least two positive results among the 
reference tests (rapid urease test, histology, and [l3C] urea breath test). 
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Table 4. Performance Characteristics of FlexPack HP, a Rapid Whole Blood Serology Test For 
H. pylori Infection, Among 100 Patients With Dyspepsia From Hong Kong 
Predictive value (% [Cl]) 
Group Number Sensitivity 
(% [Cl])a 
Specificity 
(% [Cl]) Positive Negative 
Overall 100 82 (73 - 88) 85 (74 - 92) 86 (77 - 93) 80(70 - 86) 
<= 45 years 42 73 (57 - 82) 85 (67 - 96) 84 ( 66 - 95) 74(59 - 83) 
> 45 years 58 88 (76 - 95) 85 (70 - 93) 88 (76 - 95) 85 (70 - 93) 
<= 65 years 82 80 (71 - 87) 83 (71 - 92) 86 ( 76 - 93) 77(65 - 85) 
> 65 years 18 88 (56 - 99) 90 (65 - 99) 88 (56 - 99) 90(65 - 99) 
" Cl = confidence interval 
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